Posted by Michael Wonder on 25 Mar 2021
Lamira, an eFlow rechnology nebulizer, expected to launch in Japan as a medical device for exclusive administration of Arikayce (amikacin liposome inhalation suspension)
24 March 2021 - PARI Pharma announces the authorisation of the Lamira nebuliser system for delivery of Insmed's drug product Arikayce (amikacin liposome inhalation suspension) in Japan.
Insmed was granted approval for Arikayce by Japan's Ministry of Health, Labour and Welfare on 23 March 2021. The approval of Arikayce in Japan follows earlier approvals in the United States and Europe.
Lamira is the first drug-specific eFlow Technology nebuliser registered beyond Europe and North America.
